Alexion is focused on providing innovative treatments to patients with severe and life-threatening rare diseases for which there are few, if any, effective treatment options. In 2009, Alexion began operations in Canada to serve patients locally. We aim to work in partnership with all stakeholders including healthcare providers, patient advocacy organizations and government in order to best serve patients. By expanding the knowledge and awareness of rare diseases, we help the medical community improve the process for diagnosis and treatment. Our goal is to bring hope to patients and families by delivering life-changing therapies.
In Canada, SOLIRIS® (eculizumab) has received marketing authorization from Health Canada for all patients with PNH. SOLIRIS is also approved by Health Canada as safe and effective for use in children and adults with atypical HUS to inhibit complement-mediated thrombotic microangiopathy (TMA). More recently, SOLIRIS has also been approved by Health Canada for use in adult patients with generalized Myasthenia Gravis (gMG). To further advance the understanding of PNH and atypical HUS in the Canadian population, Alexion Canada sponsors disease registries that enroll treated and untreated patients who are diagnosed with these conditions. This is our commitment to ongoing research into the rare conditions that our therapies treat.
In addition, STRENSIQ® (asfotase alfa) is approved in Canada as an enzyme replacement therapy for patients with confirmed diagnosis of paediatric-onset hypophosphatasia under the Notice of Compliance with conditions (NOC/c) policy. In addition, KANUMA® (sebelipase alfa) is approved in Canada as an enzyme replacement therapy for the treatment of infants, children and adults diagnosed with lysosomal acid lipase (LAL) deficiency, under the Notice of Compliance with conditions (NOC/c) policy.
Learn more about Alexion’s research and development efforts.
- KANUMA Product Monograph
- SOLIRIS Product Monograph
- STRENSIQ Product Monograph
- ULTOMIRIS Product Monograph
Metabolic assistance program
Alexion offers a Metabolic Assistance Program (MAP) program that provides education, assistance gaining access to STRENSIQ, and ongoing treatment support for people living with hypophosphatasia, their families and their healthcare providers. MAP also provides education, assistance gaining access to KANUMA, and ongoing treatment support for people living with lysosomal acid lipase deficiency and their healthcare providers. To learn more about MAP call 1-844-627-7262 or download the MAP brochure.
Download the STRENSIQ enrollment form
Download the KANUMA enrollment form
Alexion offers OneSource, a personalized program that provides education, assistance with access, and treatment support for patients and their caregivers. To learn more about OneSource call 1-888-765-4747, or download the SOLIRIS OneSource brochure or the ULTOMIRIS OneSource brochure.
Download the ULTOMIRIS enrollment form
Download the SOLIRIS enrollment form - aHUS
Download the SOLIRIS enrollment form - PNH
Download the SOLIRIS enrollment form - gMG
Download the SOLIRIS enrollment form - NMOSD
Working at Alexion is an experience like no other. With a focus on devastating and rare diseases, each endeavor is urgent and every day counts. Groundbreaking innovation, life-saving therapies and a promising pipeline, all driven by a team with a shared sense of purpose and dedication — that’s Alexion.
Join us to achieve the impossible and do what’s never been done before.
Browse job openings in Canada or contact:
Human Resources Canada Alexion Pharma Canada Corp.
P: +1 866.393.1188